Brad Vale, Ph.D., D.V.M.
Brad is a founding partner of Strategic Healthcare Investment Partners. He is a member of the board of directors at Nevro (NVRO), on a corporate venture advisory board for Silicon Valley Bank, along with sitting on the board of several private companies. He is a venture partner with Tramway Ventures in Albuquerque.
Brad was Head of Johnson & Johnson Development Corporation (JJDC) from 2012 to 2015. JJDC is Johnson & Johnson’s venture investing arm and has investors based in Si-Valley, Boston, Shanghai, London and Tel Aviv. He established JJDC’s west coast office in 1997 and was an investor in medical devices, healthtech, and biotech from 1992-2012.
Prior to joining JJDC, Dr. Vale supported Johnson & Johnson’s medical device businesses at the Corporate Office of Science and Technology, leading exploratory efforts in several areas, including biomaterials, intra-operative diagnostics, and lasers in medicine. He began his JNJ career at Ethicon, Inc., a Johnson & Johnson subsidiary, working on preclinical studies in wound closure, microsurgery, new business development, and a coronary artery bypass graft internal venture that was spun out of Ethicon. Dr. Vale has other experience in medical device research and development, including blood-compatible polymers, novel methods for tissue closure, and hyaluronic acid for post-operative adhesion prevention.
Dr. Vale received a PhD in Biomedical Engineering from Iowa State University and a Doctor of Veterinary Medicine from Washington State University.